FORGING A NEW PATH

Turning innovative science into transformative precision medicine

We are a pre-clinical drug development company focused on novel therapies to target kidney cancer.

In 2023, kidney cancer will afflict more than 80,000 people in the United States. The estimated 5-year survival rate for patients with metastatic kidney cancer is only 15%.  

At Kuda, our mission is to make kidney cancer a survivable disease.

We have developed a revolutionary small molecule with a dual mechanism of action of blocking the tumor driver, hypoxia-inducible factor (HIF)-2α and inducing cell death through excessive iron accumulation (ferroptosis).

The combination of ferroptosis induction + HIF-2α inhibition is a paradigm-shifting cancer treatment strategy with compelling anti-tumor activity in animal models.

In 2018, Kuda Therapeutics was awarded a $300,000 SBIR Phase 1 grant from the National Cancer Institute to develop its novel anti-cancer therapeutics.

In 2020, Kuda Therapeutics received a $560,000 Idea Award from the Department of Defense to advance its ferroptosis inducer technology.

In 2022, Kuda Therapeutics was awarded a $2,050,000 SBIR Phase II grant from the National Cancer Institute to advance this technology towards FDA Investigational New Drug (IND) filing for human proof-of-concept studies.